

1. Theriault RL, Lipton A, Hortobagyi GN et al. 
Pamidronate reduces skeletal morbidity in women with advanced breast cancer bone lesions: a randomized, placebo-controlled trial. 
Protocol 18 Aredia Breast Study Group. 
J Clin Oncol   1999;17:846-854.

2 Hortobagyi GN, Theriault RL, Porter L et al. 
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone   metastases. 
Protocol 19 Aredia Breast Study Group. 
N Engl J Med 1996;335:1785-1791.
  
9 Rogers MJ, Watts DJ, Russell RG. 
Overview of bisphosphonates. 
Cancer 1997;80(suppl 8):1652-1660.[Medline] 

10  Yoneda T, Michigami T, Yi B et al. 
Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. 
Cancer Treat Rev 1999;25:293-299.[Medline] 
 
11 van der Pluijm G, Lowik C, Papapoulos S. 
Tumour progression and angiogenesis in bone metastases from breast cancer: new approaches to an old problem.   Cancer Treat Rev 2000;26:11-27.

12  Coleman RE. 
Pamidronate disodium in the treatment and management of hypercalcaemia. 
Reviews in Contemporary Pharmacotherapy 1998;9:147-164

13 Body JJ, Bartl R, Burckhardt P et al. 
Current use of bisphosphonates in oncology. 
International Bone and Cancer Study Group. 
J Clin Oncol 1998;16:3890-3899.[Abstract] 
  
14 Body JJ, Lichinitser MR, Diehl IE et al. 
Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone. 
Proc Am Soc Clin Oncol 1999;18:575a. 
  
15 Berenson JR, Lipton A, Rosen LS et al. 
Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone   metastases. 
Blood 1998;88(suppl 1):586a. 
  
16 Vinholes JJ, Purohit OP, Abbey ME et al. 
Relationships between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic   bone disease. 
Ann Oncol 1997;8:1243-1250.  

17 Coleman RE. Biochemical markers of malignant bone disease. 
In: Rubens RD, Mundy GR, eds. Cancer and the Skeleton. London: Martin Dunitz, 2000:137-150. 
  
18 Body JJ, Coleman RE., Piccart M. 
Use of bisphosphonates in cancer patients.   
Cancer Treat Rev 1996;22:265-287.[Medline] 
  
19 Paterson AHG, Powles TJ, Kanis J et al. 
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. 
J Clin Oncol 1993;11:59-65.[Abstract] 
  
20 Lahtinen R, Laakso M, Palva I et al. 
Randomised, placebo controlled multicentre trial of clodronate in multiple myeloma. 
Finnish Leukaemia Group.   
Lancet 1992;340:1049-1052.[Medline] 

21  McCloskey EV, Maclennan ICM, Drayson M et al. 
A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. 
Br J Haematol 1998;100:317-325.[Medline] 
  
22 Conte PF, Mauriac L, Calabresi F et al. 
Delay in progression of bone metastases treated with intravenous pamidronate: results from a multicentre   randomised controlled trial. 
J Clin Oncol 1996;14;2552-2559. 
  
23 Hultborn R, Ryden S, Gunderson S et al. 
Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomised prospective double blind placebo controlled trial. 
Acta Oncol 1996;35(suppl 5):73-74. 
  
24 Berenson JR, Lichtenstein A, Porter L et al. 
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. 
J Clin Oncol 1998;16:593-602.

 25  Lipton A, Demers L, Curley E et al. 
Markers of bone resorption in patients treated with pamidronate. 
Eur J Cancer 1998;34:2021-2026.[Medline] 
  
26 Lipton A, Theriault RL, Hortobagyi GN et al. 
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast cancer and osteolytic bone metastases: long-term results of two randomised, placebo-controlled trials. 
Cancer 2000;88:1082-1090.[Medline] 
  
27 Body JJ, Lortholary A, Romieu G et al. 
A dose-finding study of zoledronate in hypercalcaemic cancer patients. 
J Bone Miner Res 1999;14:1557-1661.[Medline] 
  
28 Major P, Lortholary A, Hon J et al. 
Zoledronic acid is superior to pamidronate in the treatment of tumor-induced hypercalcamia: a pooled analysis. Proc Am Soc Clin Oncol 2000;19:604a. 
  
29 Coleman RE, Purohit OP, Black C et al. 
Double-blind, randomised, placebo-controlled study of oral ibandronate in patients with metastatic bone disease. 
Ann Oncol 1999;10:311-316.[Medline] 
  
30 Saarto S, Blomqvist C, Valimaki M et al. 
Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes   rapid bone loss which is reduced by clodronate: a randomised study in premenopausal patients. 
J Clin Oncol 1997;15:1341-1347. 
  
31 Powles TJ, Paterson AHG, Nevantaus A et al. 
Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer.   Proc Am Soc Clin Oncol 1998;17:468a. 
  
32 Diel I, Solomayer E-F, Costa SJ et al. 
Reduction in new metastases in breast cancer with adjuvant clodronate treatment. 
N Engl J Med 1998;339:357-363.
  
33 Saarto T, Blomqvist C, Virkkunen P et al. 
No reduction of bone metastases with adjuvant clodronate treatment in node-positive breast cancer patients. Proc Am Soc Clin Oncol 1999;18:128a. 
  
34 Kong Y-Y, Yoshida H, Sarosi O et al. 
OPGL is a key regulator of  osteoclastogenesis, lymphocyte development and lymph-node organogenesis.   
Nature 1999;397:315-323.[Medline] 
  
35 Honore P, Luger NM, Sabino AC et al. 
Osteoprotogerin blocks bone cancer-induced skeletal destruction. Skeletal pain and pain-related neurochemical re-organisation of the spinal cord. 
Nat Med 2000;6:521-528.[Medline]  

36 van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ et al. 
Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. 
Lancet 1987;ii:983-985.

37. Coleman, Robert E.  
Management of Bone Metastases  &&url
The Oncologist, Vol. 5, No. 6, 463-470, December 2000 

